Literature DB >> 2709033

Quantitative magnetic resonance imaging in multiple sclerosis: the effect of high dose intravenous methylprednisolone.

J Kesselring1, D H Miller, D G MacManus, G Johnson, N M Milligan, N Scolding, D A Compston, W I McDonald.   

Abstract

Magnetic resonance imaging was performed on 50 patients with clinically definite or probable multiple sclerosis before and 15 days after starting treatment with intravenous methylprednisolone (0.5 g daily for 5 days). Scans were abnormal in 49 patients. New lesions had appeared on the second scan in nine individuals and in seven a single pre-existing lesion appeared to have become smaller but in no case were lesions seen to disappear. Two patients showed both reduction in the size of an abnormal area and development of a single new lesion indicating that corticosteroids do not appear rapidly to alter the process underlying plaque formation. Measurements of relaxation times were performed in 12 randomly selected patients. All showed elevated values in normal appearing white matter but not cortex before treatment compared with 18 healthy controls. After treatment a significant decrease of T1 and T2 was observed in cortex, and of T1 alone in normal appearing white matter. No significant change could be detected within lesions, a finding attributed to the wide range of relaxation values observed at these sites before treatment. Since brain water content is increased in normal appearing white matter of multiple sclerosis patients, and is significantly reduced by high-dose methylprednisolone, resolution of oedema may contribute to the rapid spontaneous or corticosteroid induced symptomatic recovery that characterises the disease in its early stages.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2709033      PMCID: PMC1032649          DOI: 10.1136/jnnp.52.1.14

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  21 in total

1.  In vivo determination of T1 and T2 in the brain of patients with severe but stable multiple sclerosis.

Authors:  H B Larsson; J Frederiksen; L Kjaer; O Henriksen; J Olesen
Journal:  Magn Reson Med       Date:  1988-05       Impact factor: 4.668

2.  A histological, histochemical and biochemical study of the macroscopically normal white matter in multiple sclerosis.

Authors:  I V Allen; S R McKeown
Journal:  J Neurol Sci       Date:  1979-03       Impact factor: 3.181

3.  Some spaces and barriers in postmortem multiple sclerosis.

Authors:  W W Tourtellotte; J A Parker
Journal:  Prog Brain Res       Date:  1968       Impact factor: 2.453

Review 4.  Pathophysiology of demyelinating disease.

Authors:  A M Halliday; W I McDonald
Journal:  Br Med Bull       Date:  1977-01       Impact factor: 4.291

5.  Computed tomography in acute cerebral multiple sclerosis. A report of two cases.

Authors:  J Lodder; A W de Weerd; J C Koetsier; P J van der Lugt
Journal:  Arch Neurol       Date:  1983-05

6.  New diagnostic criteria for multiple sclerosis: guidelines for research protocols.

Authors:  C M Poser; D W Paty; L Scheinberg; W I McDonald; F A Davis; G C Ebers; K P Johnson; W A Sibley; D H Silberberg; W W Tourtellotte
Journal:  Ann Neurol       Date:  1983-03       Impact factor: 10.422

7.  Cranial computed tomography (CCT) findings in children treated with ACTH and dexamethasone: first results.

Authors:  I Lagenstein; R P Willig; D Kühne
Journal:  Neuropadiatrie       Date:  1979-11

8.  Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS).

Authors:  J F Kurtzke
Journal:  Neurology       Date:  1983-11       Impact factor: 9.910

9.  Possible beneficial effect of high-dose intravenous steroid therapy in acute demyelinating disease and transverse myelitis.

Authors:  P C Dowling; V V Bosch; S D Cook
Journal:  Neurology       Date:  1980-07       Impact factor: 9.910

10.  Optic nerve fibre lesions in adult cats: pattern of recovery of spatial vision.

Authors:  S G Jacobson; R A Eames; W I McDonald
Journal:  Exp Brain Res       Date:  1979-08-01       Impact factor: 1.972

View more
  15 in total

1.  Serial quantitative MR assessment of optic neuritis in a case of neuromyelitis optica, using Gadolinium- "enhanced" STIR imaging.

Authors:  F Barkhof; P Scheltens; J Valk; C Waalewijn; B M Uitdehaag; C H Polman
Journal:  Neuroradiology       Date:  1991       Impact factor: 2.804

2.  Limiting and repairing the damage in multiple sclerosis.

Authors:  A Compston
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-11       Impact factor: 10.154

3.  Evoked potential (EP) alterations in experimental allergic encephalomyelitis (EAE): early delays and latency reductions without plaques.

Authors:  D Gambi; T Fulgente; D Melchionda; M Onofrj
Journal:  Ital J Neurol Sci       Date:  1996-02

4.  Treatment with methylprednisolone in relapses of multiple sclerosis patients: immunological evidence of immediate and short-term but not long-lasting effects.

Authors:  E M Martínez-Cáceres; M A Barrau; L Brieva; C Espejo; N Barberà; X Montalban
Journal:  Clin Exp Immunol       Date:  2002-01       Impact factor: 4.330

5.  Changes within the "normal" cerebral white matter of multiple sclerosis patients during acute attacks and during high-dose cortisone therapy assessed by means of quantitative MRI.

Authors:  M Brainin; A Neuhold; T Reisner; E Maida; S Lang; L Deecke
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-12       Impact factor: 10.154

6.  High dose steroids in acute relapses of multiple sclerosis: MRI evidence for a possible mechanism of therapeutic effect.

Authors:  D H Miller; A J Thompson; S P Morrissey; D G MacManus; S G Moore; B E Kendall; I F Moseley; W I McDonald
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-06       Impact factor: 10.154

7.  Serial evoked potentials in multiple sclerosis bouts. Relation to steroid treatment.

Authors:  L La Mantia; F Riti; C Milanese; A Salmaggi; M Eoli; C Ciano; G Avanzini
Journal:  Ital J Neurol Sci       Date:  1994-10

8.  The effect of methylprednisolone on monocyte eicosanoid production in patients with multiple sclerosis.

Authors:  P F Kirk; J D Williams; M M Petersen; D A Compston
Journal:  J Neurol       Date:  1994-06       Impact factor: 4.849

9.  Serial gadolinium-enhanced magnetic resonance imaging in patients with multiple sclerosis treated with mitoxantrone.

Authors:  H Krapf; E Mauch; U Fetzer; H Laufen; H H Kornhuber
Journal:  Neuroradiology       Date:  1995-02       Impact factor: 2.804

10.  Treatment of multiple sclerosis with mitoxantrone.

Authors:  E Mauch; H H Kornhuber; H Krapf; U Fetzer; H Laufen
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1992       Impact factor: 5.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.